Case Report

Volume: 7 | Issue: 5 | Published: Aug 01, 2023 | Pages: 115 - 117 | DOI: 10.24911/ejmcr/173-1675543271

Severe acute myxedematous psychosis; rare complication of hypothyroidism


Authors: Hasnae Guerrouj , Ghizlane Ennibi


Article Info

Authors

Hasnae Guerrouj

Nuclear Medicine Department, Faculty of Medicine and Pharmacy, University Mohammed V, Rabat, Morocco

Ghizlane Ennibi

Oncology Centre of Hospital Hassan II, Agadir, Morocco.

Publication History

Received: February 05, 2023

Revised: April 21, 2023

Accepted: April 21, 2023

Published: August 01, 2023


Abstract


Background: Severe acute myxedematous psychosis, or myxedema madness, is a rare and serious psychiatric complication of hypothyroidism. It is most often misdiagnosed, but it remains reversible after treatment with thyroid hormones. Case Presentation: We report a case of a patient without a known past medical history who underwent total thyroidectomy for papillary thyroid carcinoma. During her withdrawal from thyroid hormone therapy to perform a diagnostic radioiodine wholebody scintigraphy, she presented with anxiety, delirium, and hallucinations, culminating in a suicide attempt. Laboratory testing revealed a high sensible-thyroid stimulating hormone (TSH) value of 35 µIU/ml. The patient was hospitalized in a psychiatric unit, where she received antipsychotic medication and was started on thyroid hormones. After a week, there was a dramatic improvement. Psychiatric symptoms were completely gone a month later justifying the discontinuation of antipsychotics. Recombinant human TSH (rh-TSH) was necessary injected before radioiodine therapy to avoid thyroid hormone therapy suppression and to prevent a second episode of acute psychosis. Conclusion: rh-TSH interest is both in the pre Ira therapy stimulation and for the post-treatment monitoring of patients with thyroid cancer, and helps avoiding hormonal treatment suppression.

Keywords: Myxedema, psychosis, hypothyroidism, carcinoma, rhTSH, green